Key figures and dates of the impact of Brexit for pharmaceuticals

What is the current scope of UK involvement in the pharmaceutical industry?







Pharmaceutical products are in the Top 5 most imported and exported products from the UK to the EU and vice-versa

Of these trials (based on the study duration) are expected to continue to run, post-Brexit

Source: Brexit Monitor, The impact on pharma & Life Sciences, PwC

Source: BREXIT EFPIA survey, 08/11/2017





1,165 Centrally approved products for human use

of which:

Centrally Authorised Products (CAPs) with UK based Marketing Authorization Holders


36%

Centrally Authorised Products (CAPs) with UK based Qualified Persons for Pharmacovigilance (QPPV)

27%

Source: EMA

What happens next? Key regulatory milestones for Brexit



Discuss planned variations with your EMA Project Manager

Initiate Internal Change Control Procedures to effect required variation submissions (e.g. site audits, QP contracts etc.)

Prepare and submit variation applications to the EMA

Brexit Regulatory Preparedness (all your variation applications have been submitted and/or approved)

Brexit comes into effect



CONTACT US

VCLS, Ltd. Innovation House, Albany Park Surrey GU16 7PL, Camberley, UK Phone: +44 (0) 1276 671 166 Email: vclondon@voisinconsulting.com Website: www.voisinconsulting.com

